Egan DA - Search Results

1

Methodological issues facing studies of atherosclerotic change.

Probstfield JL, Byington RP, Egan DA, Espeland MA, Margitic SE, Riley WA Jr, Furberg CD. Probstfield JL, et al. Among authors: egan da. Circulation. 1993 Mar;87(3 Suppl):II74-81. Circulation. 1993. PMID: 8443927 Review.

2

Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study.

Egan DA, Garg R, Wilt TJ, Pettinger MB, Davis KB, Crouse J, Herd JA, Hunninghake DB, Sheps DS, Kostis JB, Probstfield J, Waclawiw MA, Applegate W, Elam MB. Egan DA, et al. Am J Cardiol. 1999 Feb 15;83(4):569-75. doi: 10.1016/s0002-9149(98)00915-1. Am J Cardiol. 1999. PMID: 10073863

3

Community volunteers as recruitment staff in a clinical trial: the systolic hypertension in the elderly program (SHEP) experience.

Hertert S, Bailey G, Cottinghan V, Carmody S, Egan D, Johnson P, Probstfield J. Hertert S, et al. Control Clin Trials. 1996 Feb;17(1):23-32. doi: 10.1016/0197-2456(95)00074-7. Control Clin Trials. 1996. PMID: 8721799 Clinical Trial.

4

Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Pressel S, Davis BR, Louis GT, Whelton P, Adrogue H, Egan D, Farber M, Payne G, Probstfield J, Ward H; ALLHAT Research Group. Pressel S, et al. Control Clin Trials. 2001 Dec;22(6):674-86. doi: 10.1016/s0197-2456(01)00177-5. Control Clin Trials. 2001. PMID: 11738123 Clinical Trial.

5

Lessons learned from the DIG trial.

Egan D, Geller N, Yusuf S, Garg R, Collins JF, Mathew J, Philbin E; DIG Investigators. Egan D, et al. Control Clin Trials. 2003 Dec;24(6 Suppl):316S-326S. doi: 10.1016/s0197-2456(03)00099-0. Control Clin Trials. 2003. PMID: 14643078

6

Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease.

Garg R, Elam MB, Crouse JR 3rd, Davis KB, Kennedy JW, Egan D, Herd JA, Hunninghake DB, Johnson WC, Kostis JB, Sheps DS, Applegate WB. Garg R, et al. Am Heart J. 2000 Nov;140(5):792-803. doi: 10.1067/mhj.2000.110090. Am Heart J. 2000. PMID: 11054628 Clinical Trial.

7

Pulseless electric activity: definition, causes, mechanisms, management, and research priorities for the next decade: report from a National Heart, Lung, and Blood Institute workshop.

Myerburg RJ, Halperin H, Egan DA, Boineau R, Chugh SS, Gillis AM, Goldhaber JI, Lathrop DA, Liu P, Niemann JT, Ornato JP, Sopko G, Van Eyk JE, Walcott GP, Weisfeldt ML, Wright JD, Zipes DP. Myerburg RJ, et al. Among authors: egan da. Circulation. 2013 Dec 3;128(23):2532-41. doi: 10.1161/CIRCULATIONAHA.113.004490. Circulation. 2013. PMID: 24297818 Review. No abstract available.

8

Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research.

Libby P, Egan D, Skarlatos S. Libby P, et al. Circulation. 1997 Dec 2;96(11):4095-103. doi: 10.1161/01.cir.96.11.4095. Circulation. 1997. PMID: 9403635 Review. No abstract available.

9

Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus.

Domanski MJ, Sloas MM, Follmann DA, Scalise PP 3rd, Tucker EE, Egan D, Pizzo PA. Domanski MJ, et al. Among authors: egan d. J Pediatr. 1995 Jul;127(1):137-46. doi: 10.1016/s0022-3476(95)70275-x. J Pediatr. 1995. PMID: 7608800

10

Overview of the DIG trial.

Collins JF, Egan D, Yusuf S, Garg R, Williford WO, Geller N; DIG Investigators. Collins JF, et al. Control Clin Trials. 2003 Dec;24(6 Suppl):269S-276S. doi: 10.1016/s0197-2456(03)00104-1. Control Clin Trials. 2003. PMID: 14643073

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

117 results

Search Page

Filters